Alkermes Plc(NASDAQ) ALKS

Market Cap$7.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)+690%
5 Year+39%
1 Year+38%
1 Month-7%
Premium Feature
Moneyball Superscore
72/100
$42.78
+2.46%
+1.02Today
After hours$42.76-$0.01 (-0.04%)
Alkermes Plc last closing stock price
MetricPriceDate
Last closeUSD 42.762026-10-05
Alkermes Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.5%USD 40.152026-09-28
1 month-7.25%USD 46.102026-09-04
3 month-22.56%USD 55.222026-07-07
Year to date+52.82%USD 27.982025-12-31
1 year+37.67%USD 31.062025-10-03
3 year+51.52%USD 28.222023-10-06
5 year+39.33%USD 30.692021-10-06
Since inception+690.12%USD 5.411991-07-16

Alkermes Plc Financials at a Glance

Market Cap

$7.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.67K

Net Income (TTM)

$66.12

EPS (TTM)

$0.39

P/E Ratio

111.06

Dividend

$0.00

Beta (Volatility)

0.61 (Low)

Price

$42.78

Volume

1,460

Open

$42.07

Previous Close

$42.76

Daily Range

$41.67 - $43.22

52-Week Range

$27.00 - $55.67

Estimated Earnings Date

N/A

ALKS: Motley Fool Moneyball Superscore

72

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alkermes Plc

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Industry

Biotechnology

Employees

2,050

CEO

Richard F. Pops

ALKS Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

3.85%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

0.90%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$7.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

167.76M

Volume

1.46K

Avg. Volume

1.83M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Alkermes Plc Performance Analysis

Alkermes Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,111,795,000-5.3%
20232023-12-31USD 1,663,405,00049.6%
20242024-12-31USD 1,557,632,000-6.4%
20252025-12-31USD 1,475,899,000-5.2%
Alkermes Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.97223.0%
20232023-12-31USD 2.10N/A
20242024-12-31USD 2.173.5%
20252025-12-31USD 1.43-34.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$496.01

+1.3%

Gross Profit

$373.51

+1.1%

Gross Margin

75.30%

+0.9%

Market Cap

$7.17BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.26

N/A

Employees

2,050

N/A

Net Income

$0.50

+0.0%

EBITDA

$75.04

+0.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.08K

+250.9%

Total Debt

$1.57K

+21.6%

Accounts Receivable

$456.48

+1.3%

Inventory

$298.96

+1.6%

Long Term Debt

$1.54K

+23.2%

Short Term Debt

$33.98

+5.3%

Return on Assets

1.99%

+0.1%

Return on Invested Capital

12.94%

+1.5%

Free Cash Flow

$137.04

+1.0%

Operating Cash Flow

$145.18

+1.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About ALKS

What is the current price of Alkermes Plc?

Alkermes Plc is trading at $42.76 per share.

What is the 52-week range for Alkermes Plc?

Over the past 52 weeks, Alkermes Plc has traded between $27.00 and $55.67.

How much debt does Alkermes Plc have?

As of the most recent reporting period, Alkermes Plc reported total debt of $1.57B.

How much cash does Alkermes Plc have on hand?

Alkermes Plc reported $511.53M in cash and cash equivalents in its most recent financial results.

What is Alkermes Plc’s dividend yield?

Alkermes Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.